Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma
In patients with PHT receiving atezolizumab/bevacizumab combination therapy, PSE promotes recovery from leukopenia and thrombocytopenia. Furthermore, PSE treatment may also induce host immune activation and boost immunity.
Authors
- Akihiko Iiduka
- Ryo Sato (ORCID: https://orcid.org/0000-0002-1340-4739)
- Junji Yokoyama (ORCID: https://orcid.org/0000-0002-1810-7709)
- Takahiro Iwasawa
- Toru Ishikawa (ORCID: https://orcid.org/0000-0002-5470-9694)
- Masahiro Ogawa (ORCID: https://orcid.org/0000-0003-2154-7999)
- Toshifumi Sato
- Yuji Kobayashi
- Terasu Honma
- Nanako Terai
- HIROKI NATSUI
Institutions
- Saiseikai Niigata Daini Hospital (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13898
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32